Gramercy Property (GPT) Hold Rating Maintained by SunTrust Robinson; With $28.0 Target; Biogen Inc. (BIIB) Covered By 23 Bulls

Among 32 analysts covering Biogen Idec Inc. (NASDAQ:BIIB), 23 have Buy rating, 0 Sell and 9 Hold. Therefore 72% are positive. Biogen Idec Inc. had 98 analyst reports since July 23, 2015 according to SRatingsIntel. Cowen & Co maintained Biogen Inc. (NASDAQ:BIIB) on Tuesday, August 25 with “Buy” rating. The stock of Biogen Inc. (NASDAQ:BIIB) has “Buy” rating given on Tuesday, January 2 by BMO Capital Markets. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Buy” rating by Mizuho on Tuesday, November 8. The stock of Biogen Inc. (NASDAQ:BIIB) has “Overweight” rating given on Friday, December 18 by Atlantic Securities. Robert W. Baird downgraded it to “Neutral” rating and $316 target in Monday, July 27 report. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Market Perform” rating by BMO Capital Markets on Friday, July 24. The firm earned “Neutral” rating on Tuesday, June 7 by Citigroup. The stock has “Buy” rating by Bank of America on Wednesday, October 18. The firm has “Buy” rating given on Tuesday, November 28 by Bernstein. The stock of Biogen Inc. (NASDAQ:BIIB) earned “Neutral” rating by UBS on Wednesday, July 26. See Biogen Inc. (NASDAQ:BIIB) latest ratings:

19/01/2018 Broker: Barclays Capital Rating: Buy New Target: $395.0
18/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $407.0 Maintain
16/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $350.0 Maintain
02/01/2018 Broker: BMO Capital Markets Rating: Buy New Target: $394.0 Maintain
20/12/2017 Broker: Canaccord Genuity Rating: Hold New Target: $340.0
20/12/2017 Broker: Credit Suisse Rating: Buy New Target: $385.0 Upgrade
27/11/2017 Broker: J.P. Morgan Rating: Buy New Target: $378.0
28/11/2017 Broker: Bernstein Rating: Buy New Target: $318.0 Maintain
27/11/2017 Broker: BMO Capital Markets Rating: Buy New Target: $385.0 Maintain
08/11/2017 Broker: Oppenheimer Rating: Buy New Target: $350.0 Initiate

Among 10 analysts covering Gramercy Property Trust (NYSE:GPT), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Gramercy Property Trust has $3400 highest and $8.75 lowest target. $27.35’s average target is 4.83% above currents $26.09 stock price. Gramercy Property Trust had 16 analyst reports since August 6, 2015 according to SRatingsIntel. Bank of America downgraded the stock to “Sell” rating in Wednesday, August 16 report. The firm has “Buy” rating given on Monday, June 19 by Compass Point. MUFG Securities Americas Inc maintained the shares of GPT in report on Thursday, September 28 with “Buy” rating. The stock of Gramercy Property Trust (NYSE:GPT) has “Neutral” rating given on Monday, December 5 by Bank of America. The stock of Gramercy Property Trust (NYSE:GPT) earned “Buy” rating by Stifel Nicolaus on Friday, May 13. DA Davidson initiated Gramercy Property Trust (NYSE:GPT) on Friday, December 18 with “Buy” rating. The rating was maintained by Ladenburg on Thursday, November 9 with “Buy”. ValuEngine downgraded the stock to “Hold” rating in Thursday, May 25 report. As per Wednesday, November 1, the company rating was maintained by Ladenburg. The firm earned “Buy” rating on Wednesday, August 2 by Ladenburg.

Investors sentiment increased to 1.13 in Q3 2017. Its up 0.25, from 0.88 in 2017Q2. It improved, as 59 investors sold Biogen Inc. shares while 283 reduced holdings. 96 funds opened positions while 292 raised stakes. 181.16 million shares or 0.28% more from 180.66 million shares in 2017Q2 were reported. Greenwood Assocs Ltd invested in 11,575 shares or 0.9% of the stock. 74 were accumulated by Valley Advisers Inc. Cambridge Inv Research Incorporated has 0.03% invested in Biogen Inc. (NASDAQ:BIIB). Of Vermont reported 0.1% in Biogen Inc. (NASDAQ:BIIB). State Teachers Retirement System owns 376,420 shares. Catawba Cap Management Va reported 1,155 shares. Manchester Capital Mngmt Limited Liability invested in 1,953 shares. Caprock, a Idaho-based fund reported 3,153 shares. Moreover, Putnam Lc has 0.47% invested in Biogen Inc. (NASDAQ:BIIB) for 656,423 shares. Brown Capital Mgmt Ltd Com invested in 0.01% or 2,394 shares. Atlantic Tru Limited Co owns 16,692 shares. Alps Advisors stated it has 2,000 shares or 0% of all its holdings. Citigroup invested in 0.07% or 282,859 shares. 14,026 are owned by Associated Banc. Douglass Winthrop Advisors Limited Company invested in 2,550 shares or 0.05% of the stock.

The stock increased 0.39% or $1.32 during the last trading session, reaching $343.73. About 415,672 shares traded. Biogen Inc. (NASDAQ:BIIB) has risen 4.94% since January 22, 2017 and is uptrending. It has underperformed by 11.76% the S&P500.

Since January 9, 2018, it had 0 insider buys, and 1 insider sale for $1.92 million activity. The insider PANGIA ROBERT W sold 5,832 shares worth $1.92M.

Biogen Inc., a biopharmaceutical company, discovers, develops, makes, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company has market cap of $72.69 billion. The firm offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis ; FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It has a 21.12 P/E ratio. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies.

Gramercy Property Trust is a leading global investor and asset manager of commercial real estate. The company has market cap of $4.26 billion.